Ependymoma clinical trials

Explore recruiting ependymoma clinical trials.

Recruiting ependymoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Ependymoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

SIOP Ependymoma Program II: An International Clinical Program for the diagnosis and treatment of children, adolescents and young adults with ependymoma

France, Italy, Denmark, Austria, Netherlands, Norway +7 more

Phase II and Phase III (Integrated) EU CTIS Study details

MEPENDAX: Phase I/II study of axitinib (Inlyta®) and oral metronomic etoposide for pediatric children and AYA with refractory/relapsing medulloblastoma and ependymoma

France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

MEMMAT - Medulloblastoma European Multitarget Metronomic Anti-Angiogenic Trial - A Phase II study of metronomic and targeted anti-angiogenesis therapy for children with recurrent/progressive medulloblastoma, ependymoma, ATRT and rare CNS tumors

Austria, Czechia, France, Norway, Spain, Sweden +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Metro-PD1-1708: a phase I/II trial evaluating anti-PD1 (Nivolumab) in combination with metronomic chemotherapy in children and teenagers with refractory /relapsing solid tumors

France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

PNOC023: Open Label Phase 1 and Target Validation Study of ONC206 in Children and Young Adults with Newly Diagnosed or Recurrent Diffuse Midline Glioma (DMG), and Other Recurrent Primary Malignant Central Nervous System (CNS) Tumors.

Netherlands

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Ependymoma trials by city

Ependymoma in Toronto Ependymoma in Vancouver Ependymoma in Montreal Ependymoma in Calgary Ependymoma in Edmonton Ependymoma in Ottawa Ependymoma in Winnipeg Ependymoma in Quebec City Ependymoma in Hamilton Ependymoma in Kitchener Ependymoma in London Ependymoma in Halifax Ependymoma in New York Ependymoma in Los Angeles Ependymoma in Chicago Ependymoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease